在患有抑郁症和没有抑郁症的高血压患者中表达内甲素-1,中白素-6和c-kit的表达差异和关系
Wei-Yi Wang1,2, Yi Wu1, Jing-Qi Zhang1,2
1The Clinical Research Center for Acute Myocardial Infarction of Hubei Province, Xianning Central Hospital, First Affiliated Hospital of Hubei University of Science and Technology, Xianning 437000, Hubei Province, China.
World journal of psychiatry
|July 31, 2025
概括
患有抑郁症的高血压显示内甲素-1 (ET-1) 和白内素-6 (IL-6) 水平升高,以及干细胞因子 (SCF) 和c-kit.kit的降低. 这些生物标志物组合为这种疾病提供了高的诊断价值.
科学领域:
- 心血管研究研究心血管研究
- 临床心理学 临床心理学
- 生物标志物发现发现
背景情况:
- 高血压是一种普遍的心血管疾病,对健康和经济造成重大负担.
- 它与心血管事件和器官损伤的风险增加有关.
- 伴随性抑郁症加剧了高血压的影响.
研究的目的:
- 研究ET-1,IL-6,SCF和c-kit在患有抑郁症和没有抑郁症的高血压患者中的差异表达.
- 探索这些生物标志物与抑郁症严重程度之间的关系.
- 评估这些生物标志物的高血压与抑郁症的诊断效用.
主要方法:
- 对163名高血压患者的回顾性分析 (A组:患有抑郁症,n=77;B组:没有抑郁症,n=86).
- 血清ET-1和IL-6通过放射性免疫检测测量;SCF和c-kit通过ELISA测量.
- 进行了相关性,逻辑回归和ROC曲线分析.
主要成果:
- 患有抑郁症的高血压患者 (A组) 的ET-1和IL-6高,SCF和c-kit低于B组 (P<0.05).
- 生物标志物水平与抑郁症严重程度相关 (HAMD分数).
- 与单个标志物相比,联合ET-1,IL-6,SCF和c-kit显示出更高的诊断值 (AUC=0.884).
结论:
- 升高的ET-1和IL-6,以及降低的SCF和c-kit,具有伴随性抑郁症的高血压的特征.
- 这些生物标志物是抑郁症高血压的独立影响因素.
- 对ET-1,IL-6,SCF和c-kit的联合检测具有显著的诊断潜力.
相关概念视频
Hypertension II: Pathophysiology
79
Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
79
Hypertension III: Clinical Manifestations and Diagnostic Studies
48
Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
48
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
225
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
225
Hypertension I: Introduction
76
Hypertension is a widespread, long-term medical condition where blood pressure in the arteries remains elevated. It is characterized by systolic blood pressure readings of 130 mm Hg or above or diastolic blood pressure (DBP) readings of 80 mm Hg or higher. Unmanaged hypertension poses significant health risks, making the distinction between primary (or essential) hypertension and secondary hypertension crucial, as their management and implications vary.Primary HypertensionPrimary hypertension,...
76
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
888
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
888
Hypertension and Regulation of Blood Pressure
3.1K
Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
3.1K


